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CHAPTER 1
Introduction
Human Immunodeficiency Virus (HIV) is the virus that causes acquired immunodeficiency syn-
drome (AIDS). Being a member of a group of viruses called retroviruses, HIV infects human
cells and uses the energy and nutrients provided by those cells to grow and reproduce. AIDS
is a disease in which the body’s immune system breaks down and is unable to fight off cer-
tain infections, known as ”opportunistic infections”, and other illnesses that take advantage of
a weakened immune system. When a person is infected with HIV, the virus enters the body
and lives and multiplies primarily in the white blood cells. These are the immune cells that
normally protect us from disease. The hallmark of HIV infection is the progressive loss of a
specific type of immune cell called T-helper or CD4 cells. As the virus grows, it damages or
kills these and other cells, weakening the immune system and leaving the individual vulnerable
to various opportunistic infections and other illnesses, ranging from pneumonia to cancer [1].
The U.S. Centers for Disease Control and Prevention (CDC), [2], defines someone as having a
clinical diagnosis of AIDS if they have tested positive for HIV and meet one or both of these
conditions:
• They have experienced one or more AIDS-related infections or illnesses
• The number of CD4 cells has reached or fallen below 200 cells per cubic milliliter (µL)
of blood (a measurement known as T-cell count)
In healthy individuals, the CD4 count normally ranges from 450 to 1200 cells/µL.
For many years, there were no effective treatments for AIDS. Today, people in the United States
and other developed countries can use a number of drugs to treat HIV infection and AIDS.
Some of these are designed to treat the opportunistic infections and illnesses that affect people
with HIV/AIDS. In addition, several types of drugs seek to prevent HIV from reproducing and
destroying the body’s immune system. Many HIV patients are taking several of these drugs in
combination a regimen known as highly active antiretroviral therapy (HAART). When success-
ful, combination or ”cocktail” therapy can reduce the level of HIV in the bloodstream to very
low, even undetectable, levels and sometimes enable the body’s CD4 immune cells to rebound
to normal levels.
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Researchers are working to develop new drugs known as fusion inhibitors and entry inhibitors
that can prevent HIV from attaching to and infecting human immune cells. Efforts are also
underway to identify new targets for anti-HIV medications and to discover ways of restoring
the ability of damaged immune systems to defend against HIV and the many illnesses that af-
fect HIV-infected individuals. Ultimately, advances in rebuilding the immune system in HIV
patients will benefit people with a number of serious illnesses, including cancer, Alzheimer’s
disease, multiple sclerosis, and immune deficiencies associated with aging and premature birth
[1].
With around 2.6 million people becoming infected with Human Immunodeficiency Virus in 2009,
there are now (October 2011) an estimated 33 million people around the world who are living
with HIV, including millions who have developed AIDS, [3]. Since the beginning of the epidemic,
AIDS has killed nearly 19 million people worldwide. AIDS has replaced malaria and tuberculosis
as the world’s deadliest infectious disease among adults and is the fourth leading cause of death
worldwide. In 2008 299 persons were reported diagnosed with HIV in Norway, and of these, 18
persons got AIDS. 12 of the persons with AIDS died because of it [4].
There is still no cure for AIDS, and while new drugs are helping many people with HIV/AIDS
live longer, healthier lives, there are many problems associated with them [1]:
• Existing treatments do not work for many people with HIV/AIDS
• Anti-HIV drugs are highly toxic and can cause serious side effects, including heart
damage, kidney failure, and osteoporosis. Many (perhaps even most) patients cannot
tolerate long-term treatment with HAART
• HIV mutates constantly. In as many as 40% of people on HAART, HIV mutates into
new viral strains that have become highly resistant to current drugs, and as many as
10% of newly infected Americans are acquiring drug-resistant strains of the virus
• Because treatment regimens are unpleasant and complex, many patients occasionally
miss doses of their medication. Failure to take anti-HIV drugs on schedule and in the
prescribed dosage can encourage the development of new viral strains that are resistant
to current HIV drugs
• Even among those who do respond well to treatment, HAART does not eradicate HIV.
The virus continues to replicate at low levels and often remains hidden in ”reservoirs”
in the body, such as the lymph nodes and brain
Importantly, roughly 95% of all people with HIV/AIDS live in the developing world, where
there is virtually no access to antiretroviral treatments. In the U.S. HAART contributed to a
significant decline in the annual number of AIDS-related deaths between 1996 and 1998. But the
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rate of this decline has now slowed markedly, and some communities are reporting an increase
in AIDS deaths.
When estimating the effect of a therapy such as HAART on progression to AIDS or death, proper
methods for modelling is of great importance. Standard methods like Cox and logistic regressions
in observational studies will fail to properly correct for the time-dependent confounders that are
also affected by previous treatment. Thus the estimates from these methods will be biased. In the
growing field of Causality there has been developed several methods to overcome this problem.
One of them is the Marginal Structural Model (MSM). The parameters of a MSM can be
consistently estimated using the inverse-probability-of-treatment weighted (IPTW) estimators
[5].
The aim of this thesis is the show the use of the Marginal Stuctural Model introduced by Robins
[6]. The model will be presented in a biological context and applied to a training set of the Swiss
HIV cohort [7] and some simulated data sets.
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CHAPTER 2
Survival Analysis
2.1. Basic Concepts
Survival analysis deals with occurrences of events in different scientific studies, especially in
medical research and statistics. Such events could be marriage, birth, graduation from school,
failure in mechanical systems and so on. The term survival time doesn’t necessarily have any-
thing to do with death; it is the time from an initiating event to the time of the event of interest.
The event of interest in my thesis is progress to AIDS or death and here the survival time is the
time from treatment of HAART to the event.
Some subjects involved in a study will experience the event of interest, and others will maybe
experience the event after the end of the study, or not even then. This leads to a censored data
set consisting of complete and incomplete observations. The methods of survival analysis are
specially developed for the handling of this kind of data.
2.1.1. Survival Function. The survival function specifies the unconditional probability
that the event of interest has not happened by time t and is given by
S(t) = P (T > t)
where T denotes the survival time.
The survival function can also be looked at as the expected proportion of individuals for which
the event has not happened by time t. Since more and more subjects experience the event over
time the survival function decreases towards zero as t increases. In the situations where not all
individuals experience the event, the random variable T may be infinite. Then S(t) decreases
to a positive number as T goes to infinity.
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2.1.2. Hazard Rate. The hazard rate represents the instantaneous event rate for an indi-
vidual who has already survived to time t and is given by
α(t) = lim
∆t→0
1
∆t
P (t ≤ T < t+ ∆t|T ≥ t)
α(t)dt is the probability of experiencing the event in the small time interval [t, t+ dt).
Here it is assumed that T is absolutely continuous, meaning that it has a density function. α(t)
can be any nonnegative function.
The relationship between S(t) and α(t) is given by
α(t) = −S
′(t)
S(t)
The hazard ratio is the ratio of the hazard rates in two groups, for instance the group with
treatment and the group without treatment. The hazard ratio is commonly used when present-
ing results in clinical trials involving survival data.
2.2. Cox Regression
The Cox model is a statistical technique for exploring the relationship between the survival of a
patient and several explanatory variables. It is the most commonly used multivariate approach
for analyzing survival time data in medical research. The method is based on an assumption
that the hazards remain proportionately constant and it is more correctly called the Cox pro-
portional hazards model.
For the Cox model the hazard rate for individual i with vector of covariates xi(t) = (xi1(t), . . . ,xip(t))T
is given by
α(t|xi) = α0(t)exp{βTxi(t)} (2.1)
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We have to look at a partial likelihood for the inference on the regression coefficients because of
the semi parametric nature of (2.1).
Each individual i in the study has a counting process Ni(t) counting the number of occurrences
of the event of interest in [0, t]. Ni(t) = 1 if by time t the event has occurred for individual i,
otherwise Ni(t) = 0. We assume that at time t for individual i the components of xi(t) are
fixed or time-varying, and that the intensity process of Ni can be written as
λi(t) = Yi(t)α(t|xi)
where Yi(t) = 1 if individual i is at risk for the event just before time t and Yi(t) = 0 otherwise.
By using (2.1) the intensity process of Ni can be written as
λi(t) = Yi(t)α0(t)exp{βTxi(t)}
When registering events among all individuals we need the aggregated counting process N(t) =∑n
l=1Nl(t) with intensity process
λ(t) =
n∑
l=1
Yl(t)α0(t)exp{βTxl(t)}
A factorization of the intensity process of Ni(t) is given by λi(t) = λ(t)pi(i|t) where
pi(i|t) = λi(t)
λ(t)
=
Yi(t)exp{βTxi(t)}∑n
l=1 Yl(t)exp{βTxl(t)}
(2.2)
is the conditional probability of observing an event for individual i at time t, given the past and
that an event is observed at that time.
Assuming that we have no tied events, meaning that no events happen at the same time, we
denote the times when events are observed by T1 < T2 < · · · . The partial likelihood is obtained
my multiplying the conditional probabilities (2.2) over all event times, and when ij is the index
of the individual experiencing the event Tj , it becomes
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L(β) =
∏
Tj
pi(ij |Tj) =
∏
Tj
Yij (Tj)exp{βTxij (Tj)}∑n
l=1 Yl(Tj)exp{βTxl(Tj)}
(2.3)
The Yij (Tj) in the numerator is always equal to one because the individuals experiencing the
events are at risk just before the event times Tj . Defining the set of individuals who are still
under study at time just before Tj as the risk set Rj = {l|Yl(Tj) = 1},(2.3) can be written as
L(β) =
∏
Tj
exp{βTxij (Tj)}∑
l∈Rj exp{βTxl(Tj)}
By maximizing the Cox log partial likelihood
l(β) =
∑
Tj
βTxij (Tj)− log ∑
l∈Rj
exp{βTxl(Tj)}

we can estimate the regression coefficients in the Cox model. A positive coefficient will increase
the hazard contributing negative on the survival, and a negative coefficient will decrease the
hazard contributing positively in the survival.
The log hazard rate is given as
log(group hazard/baseline hazard) = log((h(t)/h0(t)) =
∑
i
βixi (2.4)
A unit increase in the independent variable i is associated with βi increase in the log hazard
rate.
2.3. Pooled logistic regression and the equivalence to Cox regression
In cohort studies in medical and epidemiological research a group of individuals is followed up
for a study period of many years. Data about risk factors, an outcome of interest and other
variables are collected repeatedly in set intervals of equal length over the study period. This
repeated collection of data leads to several observations for each individual in the study. The
interest is to evaluate the relationship between different risk factors to the outcome and the
question is how to do this with the repeated observations.
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The solution is to treat every interval as a mini follow-up study, pool the observations of all
intervals together to one pooled sample, and do a logistic regression on the pooled data set.
This is referred to as pooled logistic regression [8].
With this pooling method one single individual can contribute several times to the data set, or
person-time. For each interval where the individual does not experience an event of interest or
is not lost to follow-up for some reason, the individual can be carried on to be part of the risk
set for the next period. It then counts as a new observation in the next interval.
 40 events 
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25 events 
 
 
5 lost to 
follow-up 
20 events 
 
 
10 lost to 
follow-up 
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Figure 2.1. Pooling of repeated measurements
It is easier to explain the pooling method with the example that illustrates this type of pooled
data from Figure 2.1. Imagine that 1000 patients enter a hypothetical study with 4 visits at
times t0, t1, t2 and t3. Their risk factors are measured at the first visit and they are all at risk for
the event at t0. At the end of the first interval, 40 patients may have experienced the event, and
10 may have been lost to follow-up. The 40 events are recorded, and the 50 patients experiencing
the event or being lost to follow-up are removed from the risk set. The remaining 950 patients
are measured at the second visit carried on forming the risk set at time t1. At the end of the
interval starting at time t1, there has been 25 events and 5 patients lost to follow-up. These 30
patients are removed from the risk set, leaving 920 patients at risk at time t2 with risk factors
being measured at the third visit. From t2 to t3 there has been 20 events and 10 patients lost to
follow up. So the 1000 patients who entered the study contributed with 1000+950+920 = 2870
person-time as if they were individual observations. In total there were 40+25+20=85 events.
The pooled data set consists of 2870 observations with 85 events, and a logistic regression is
performed on this pooled sample.
With very short intervals, the probability of an event happening in an interval is very small and
the intercept for the pooled logistic regression is constant. When this is the case the model of
pooled logistic regression is asymptotically equivalent with the Cox time-dependent regression
model [9], meaning a Cox regression model with time-dependent covariates.
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The logistic regression model is written:
logitqi(X(ti−1)) = log
(
qi(X(ti−1))
1− qi(X(ti−1))
)
= αi + β1Xi(ti−1) + . . .+ βpXp(ti−1),
where qi(X(ti−1)) is the conditional probability of observing an event by time t1 given that
the individual is event free at time ti−1, and X(ti−1) = (X1(ti1), . . . , Xp(ti1)) is the risk factors
measured at time ti−1. The intercept αi is a function of the time between visit i− 1 and visit i.
When the risk factors are recorded at times t0, t1, . . . (Figure 2.1) and the observations are
grouped into intervals [ti−1, ti] then the hazard rate in the time dependent covariate cox regres-
sion is given:
pi(X(ti−1)) = exp
{
−
∫ ti
ti−1
h0(u)exp[β′X(ti−1)]du
}
.
pi(X(ti−1)) denotes the probability that an individual will survive up to time ti given survival
up tp time ti−1. h0(u) is the baseline hazard rate and β′X(ti−1) = β1X1(ti1) + . . .+βpXp(ti1) is
the linear function of the Cox proportional hazard model. In this model the events are grouped
into intervals [ti−1, ti] but not specified as to a time of occurrence within the intervals. This is
the grouped Cox model.
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Causality
Causality is based on the notion of the past influencing the present and the future [10]. Under-
lying the concept of causality is the simple word cause and in questions of causal matters the
relationship between cause and effect is explored closely. When practising causal inference, it
is important to bear in mind that there is a difference between association and causation. Just
because studies in children have revealed that shoe size is positively associated with literacy, it
does not automatically imply that becoming more literate makes your feet grow or vice versa.
The groups of children that are compared may not be comparable because they differ in terms
of factors other than their literacy score, age for instance.
In life we are exposed to interventions for the achievement of different goals. It could be a
medicine prescribed from a doctor to cure a disease. The medicine is supposed to have a specific
causal effect on the disease. Before the medicine is put on the marked, it is put through a
long process of research and clinical testing. We need some understanding of how for example
the body or viruses respond to certain substances. What lies behind causality is the search
for a mechanistic understanding of connections surrounding specific factors. This mechanistic
understanding is very limited when it comes to medicine because of the complexity and the
countless number of causal connections in the body. In some cases there are some ethical
limitations to the interventions and experiments, but the aim to understand the effect of the
interventions is still there. In other cases we know the causal pattern already because some
variables are known earlier than others. University grades will for instance have no impact on
high school grades, but rather the other way around.
We want a clear overview of the causal connections between the factors involved in a study not
to make the mistake of misinterpreting associations and direct effects. The connections between
the variables can be summed up using graphical models that show how the different variables
influence one another. One example of a graphical model is the DAG, directed acyclic graph.
3.1. DAG
A causal diagram is a system of nodes and edges, based on expert knowledge that represents
all causal influences between all relevant observed variables. With this graphical representation
we can gain insight whether the effect of one variable on another is identified and how it can be
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estimated. An example of a causal diagram is a DAG, Directed Acyclic Graph. The DAG is a
system of directed edges (arrows) between variables but without cycles. Each edge on the DAG
represents a possible direct causal relationship between two variables, and the absence of an
edge represents the assumption that there is no direct causal relationship between the variables.
All common causes of any two variables are included as a variable on the DAG. Thus a causal
DAG does not have to include variables that are not of interest and not a common cause of two
variables in the DAG. In other words, there are no omitted confounders in the DAG.
 
A Y 
I 
U 
Figure 3.1. DAG
Figure 3.1 is an example of a DAG with only one time point. A can be an exposure of some
kind and Y a specific outcome. Then I could be a vector of all measured risk factors for Y ,
and U all unmeasured risk factors for Y . One variable can only causally affect another variable
when there is a directed path between the two. In the example of Figure 3.1 A may have a
direct causal effect on Y as well as an indirect causal effect which is mediated by I. A does not
causally affect Y along the path A− I − U − Y . But two variables can be associated along all
directed and undirected paths that connect the two. With a graphical rule called d-separation,
we can decide whether a conditional association between measurements reflects causation under
the assumptions of the causal diagram.
3.1.1. d-separation. d-separation is a graphical rule to verify independence between vari-
ables based on a DAG. A collider is a node with two or more arrows pointing to it. If we think
of the DAG as an electric circuit, the colliders are switches that are turned off (inactive), and
the non-colliders are switches that are turned on (active). If there is no electric current between
two variables they are independent. There may be association between two variables along all
active paths. The association between A and Y in Figure 3.1 is due to the direct causal effect
and the indirect causal effect through I. But the path A − I − U − Y is inactive because of
the collider I and does not associate A and Y . If we do an analysis and restrict the analysis to
subjects with the same value of I or include I in a regression model E(Y |A, I) = α+ βA+ γI,
we ”adjust the analysis for I”. With the rules of d-seperation we can evaluate whether A and Y
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are conditionally independent. Adjusting for non-colliders changes them from active to inactive
and adjusting for colliders or their descendants changes them from inactive to active. If there
is no electric current between A and Y after adjusting for I, they are conditionally independent
given I.
For example adjusting for I in Figure 3.1 closes the A− I − Y path but opens the A− U − Y
path. The conditional association between A and Y is thus due to the direct causal effect and
the spurious association through the unobserved U , but not due to the indirect causal effect
through I. It’s important not to ignore the possible presence of confounders for the association
between mediator and outcome. The approaches of a traditional mediation analysis with the
adjustments are invalid in the presence of confounders U . The reason for this is that they try
to uncover causation merely from statistical associations, but association 6= causation. Thus
it is very important to express background knowledge when we want to learn about the effect
of some exposure on some outcome. Using d-separation, we can infer for which confounders we
need to adjust when estimating the causal effect of A on Y .
I 
 
A Y 
L U 
Figure 3.2. DAG
Conditional association between A and Y in Figure 3.2 given I and L reveals the direct effect
of A on Y . Thus when we fit model
E(Y |A, I, L) = α+ βA+ γY + δL
then β measures the direct effect of A on Y .
3.2. Time-dependent confounding and complications
A confounder is a common predictor of two or more variables and it is time-dependent when it
varies with time. In this case with the observational study of HIV patients, looking on the effect
13
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Treatment Event 
CD4 
Figure 3.3. Confounding between treatment and event
of a treatment (exposure) on time to AIDS or death (event), the time-dependent confounder
has an impact on both the event and also on treatment. One example of this type of confounder
is the CD4 count. The CD4 cells are one of the different types of cells that help protect the
body from infection, and the CD4 count, among other factors, implies the severity of the HIV
disease. The higher the number of CD4 cells in the blood the better the immune system. HIV
attacks these types of cells and weakens the immune system. An HIV patient is classified as
having AIDS when the CD4 count drops below a certain limit. So the CD4 count affects the
event. The CD4 count is also used in the decision of when to initiate the HIV treatment. Thus
the CD4 count confounds the relationship between treatment and the event, see Figure 3.3 for
this simple example with only one time point.
The reality is that CD4 count is also affected by treatment and this is when we get a feedback
relationship between treatment and CD4, they both affect each other. The CD4 is a confounder
of the relationship between treatment and event, but is also a mediator on the causal path from
treatment to event. Thus CD4 is an intermediate time-dependent confounder and with
this follows complications.
A bit more complex and general example of a DAG is given in Figure 3.4. Here possible
relationships between the variables are given with two time points, k = 1, 2.
• Ak is the exposure at time k
• Y is the outcome
• Lk is a vector of all measured risk factors for the outcome at time k
• Uk is all unmeasured risk factors for the outcome at time k
From Figure 3.4 we can see that L is an intermediate time-dependent confounder of the rela-
tionship between exposure and outcome. The causal effect of exposure on outcome is divided
on four different directed paths: A0 − A1 − Y , A1 − Y , A0 − L1 − A1 − Y and A0 − L1 − Y ,
describing direct and indirect effects of exposure. To model this effect we could fit a standard
regression model adjusted for exposure A:
14
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𝐴0 𝐴1 Y 
𝐿1 𝐿0 
𝑈0 𝑈1 
Figure 3.4. Intermediate time-dependent confounding
E(Y |A1, A0) = ω + β0A0 + β1A1
The setting of Figure 3.4 together with the rules of d-separation, explained in subsection 3.1.1,
shows that adjusting for A0 and A1 opens the undirected paths through L0 and L1. Thus the
estimated exposure effect from the standard regression model is not the causal effect that we
wish to estimate. We could try to adjust for L0:
E(Y |A1, A0, L0) = ω(L0) + β0A0 + β1A1
Even though this closes one of the non-causal paths through L0 there is still the undirected path
from exposure going through L1. So the problem from the first standard model is the same. We
could adjust for L1 in the regression model as well:
E(Y |A1, A0, L0, L1) = ω(L0, L1) + β0A0 + β1A1
Again with the rules of d-separation we see that this not only closes parts of the causal effect,
going from A0 along L1, but also opens the spurious association between A0 and Y through U1.
As this variable is unmeasured, it cannot be adjusted for.
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The problem with these standard approaches is that they all fail to reflect the causal effect of
exposure. We need to adjust for L as it confounds the A−Y relationship, but we are not allowed
to do this adjustment because it removes part of the causal effect and also creates a spurious
association. The problem of the possible presence of unmeasured factors U , that are associated
with outcome and the confounders, needs to be taken into account.
3.3. Marginal Structural Models
Marginal Structural Models (MSM) belong to a class of causal models used for the estimation
of the causal effect of a time-dependent exposure in the presence of time-dependent covariates
that are themselves affected by previous treatment. The effect is modelled using counterfactual
outcomes. The MSM is marginal because it describes the effect of the exposure on the marginal
distribution of the counterfactual outcomes and structural because models for counterfactual
random variables are called structural in the social and economic sciences [11]. The parameters
of the MSM can be estimated using inverse-probability-of-treatment weights. Valid causal in-
ferences can be drawn by comparing the subjects who are on treatment with the patients who
are off treatment in different time intervals. Thus the same patients represent observations in
different treatment groups.
The model is fitted in two stages [12]:
(1) estimation of each subject’s probability of having their own treatment history and
calculation of inverse-probability-of-treatment weights (IPTW)
(2) the effect of treatment is estimated in a regression model that is weighted using the
IPTW’s
The marginal structural model is based on some assumptions:
(1) there are no unmeasured confounders
(2) the marginal structural model for the effect of HAART on AIDS or death among the
HIV patientes is correctly specified
(3) the model for initiation of treatment is correctly specified
3.3.1. Counterfactuals. The concept behind counterfactual thinking is to imagine what
might happen if possibilities other than the actual one did occur. We look at an underweight
new born child whose mother smoked during the pregnancy. What would have happened with
the weight of the child hadn’t the mother smoked? This possibility is ”counter to fact”. In this
case we can only observe one of the outcomes of the ”treatment” (smoking), but the idea is to
mimic the other outcome and compare both possibilities.
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We denote Ta¯ as the subject’s time to event (e.g failure time) had he received treatment history
a¯ rather than his observed history. We only observe the failure times where Ta¯ = T where T is
the observed time to event, the other values of Ta¯ being counterfactuals. For each a¯ we specify
the marginal structural Cox proportional hazards model
αTa¯(t|V ) = α0(t)exp{β0a(t) + β1V }
where αTa¯(t|V ) is the hazard of the event at time t among subjects with baseline covariates
V had they all followed treatment history a¯. β0 and β1 are the unknown parameters to be
estimated and α0 is an unspecified baseline hazard function.
3.3.2. Inverse-probability-of-treatment (IPT) weights. A pseudo population in which
the risk factors no longer confound the relationship between treatment and outcome is created
using IPT weights. Each subject gets weighted according to the subject’s probability of having
its observed treatment given the observed covariates for every time point. This way the subjects
contribute to the new risk set with copies of themselves. The rare cases get up-weighted and
the most common cases get down-weighted. The initiation of treatment in the reweighted set is
no longer dependent on the risk factors. An example of a rare case is a subject with small prob-
ability of getting treatment who starts treatment. An example of a common case is a subject
with big probability of starting treatment who starts treatment.
It is common to define the weights based on a discretization of the time interval. The IPT
weight for subject i is given by
wi(t) =
int(t)∏ 1
P (A(k) = ai(k)|A¯(k − 1) = a¯i(k − 1), L¯(k − 1) = l¯i(k − 1))
(3.1)
The probability of starting treatment may vary greatly among the subjects leading to unstable
weights. A few subjects may get very large weights and with this contribute to the pseudo
population with a large number of copies of themselves. These subjects will dominate the
weighed analysis.
The stabilized version of inverse-probability-of-treatment weight is given by
swi(t) =
int(t)∏ P (A(k) = ai(k)|A¯(k − 1) = a¯i(k − 1), V = v)
P (A(k) = ai(k)|A¯(k − 1) = a¯i(k − 1), L¯(k − 1) = l¯i(k − 1))
(3.2)
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where A¯(−1) = 0. This results in weights that are less variable, are centered around 1 and are
closer to the normal distribution.
Each factor of the denominator of swi(t) is the probability that the subject received his own
observed treatment at month k, given his past treatment and prognostic factor history, where
V is included in L(0). Each factor in the numerator is the probability that the subject received
his own treatment conditional on his past treatment history and baseline covariates, but not for
the time-dependent confounders.
Weighting by swi(t) creates the pseudo population we want where L¯(t) no longer predicts the
initiation of HAART at time t, that is, L¯(t) is no longer a confounder of the treatment-event
relationship.
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A training set provided by Jonathan A. C. Sterne
The Swiss HIV Cohort Study is an on-going multi-center research project in Switzerland that
was established in 1988, dealing with HIV infected adults aged 16 years and older [7]. After
HAART was introduced in Switzerland in 1996, Sterne et al [13], published an article with a
study looking at the effectiveness of antiretroviral therapy in preventing AIDS and death using
data from the Swiss HIV Cohort Study. The estimation of the treatment effect is calculated
using the method of MSM. Jonathan A. C. Sterne has been so kind to provide a training set
consisting of a small part of the data set used in the study. With this training set comes a
sheet of commands of how to analyze the data set in the statistical software Stata . Since I am
not very familiar with this program I use this training set and methods in Stata to create an
equivalent program in R. I compare the results from the two programs to make sure that I have
the right programming base in R for further demonstration of the MSM.
The event of interest in the training set is AIDS or death. The training data set is split into
monthly intervals and contains the following information about the patients for each month:
• Cd4 - current CD4 group - lowest CD4 (≤ 50) is the reference
• Rna - current plasma HIV-1 RNA group - highest RNA (≥ 100,000) is the reference
• LCd4 - lagged (three months previous) CD4 group
• LRna - lagged (three months previous) plasma HIV-1 RNA group
• BCd4 - baseline CD4 group
• BRna - baseline (three months previous) plasma HIV-1 RNA group
• A - age group
• Y - current year (from 1996, with 2001 as the reference year)
• Group - transmission risk group (with men who have sex with men (MSM) as the
reference group)
There are a lot of similar lines for each patient. If there is no new observation for one month,
the observation from the previous month is used.
Patients were exluded from the study if they:
• died or refused further participation before 1996
• were on HAART or had the AIDS diagnosis at the first follow up visit
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• had an uncertain treatment history before joining the study
The data set contains measurements of CD4 count, HIV-1 RNA, hemoglobin, information of
which treatment was taken (monotherapy, dual therapy or HAART, and information on whether
the patients experienced a CDC stage B, i.e. got a CD4 count from 200-499 cells/µL [2]. The
CD4 count is as desbribed in Chapter 1 a count of a specific type of immune cells in the body.
The HIV-1 RNA is the RNA copies per millimeter of blood plasma. The CD4 count and HIV-1
RNA are used as markers for the severity of the HIV infection [15]. Hemoglobin in the blood
carries oxygen from the lungs to the rest of the body where it releases the oxygen to burn
nutrients to provide energy to power the functions of the organism, and collects the resultant
carbon dioxide to bring back to the lungs to be dispensed from the organism [16].
The first monthly visit after January 1996 for which each variable was available was the baseline
month. To get more conservative estimates it was assumed that treatment was started at the
end of the month before they actually started the treatment. Another assumption was that once
treatment was started the patient stayed on it.
I do unweighted Cox analyses in Stata with the recipe I received from Sterne using:
(1) treatment as the only covariate
(2) treatment and baseline covariates
(3) treatment, baseline, and time-updated covariates
Analysis HR SE P-value 95% C.I
(1) 0.75 0.20 0.14 [0.51, 1.10]
(2) 0.37 0.22 0.00 [0.24, 0.56]
(3) 0.72 0.23 0.15 [0.45, 1.13]
Table 4.1. Unweighted Cox analyses in Stata
The only significant result from Table 4.1 is the analysis where treatment and baseline covariates
are used. It shows that the hazard for AIDS or death is reduced with 63% for the patients on
treatment compared to the patients not on treatment. It is clear that HAART has an effect.
Analysis HR SE P-value 95% C.I
MSM 0.15 0.22(0.08∗) 0.00 [0.12, 0.23]∗
Table 4.2. Weighted Cox analysis in Stata
*Estimated from boostrap sampling.
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The overall hazard ratio from the weighted Cox analysis in Table 4.2 is 0.15(0.12, 0.23) for
treatment compared with no treatment. This result is significant and shows a much stronger
effect of treatment than the unweighted analyses. The hazard for AIDS or death is now reduced
with 85% for the patients on treatment. This result coincides with the overall hazard ratio in
the study by Sterne et al [13], even though the data set used here is much smaller than the data
set in the study.
The MSM gives a more realistic estimate of the treatment effect than the standard unweighted
analyses, especially compared to the significant result of the unweighted Cox where treatment
and baseline covariates were used. The fact that the patitients starting treatment generally have
a severe HIV infection, and therefore a bigger chance of getting AIDS or dying, is not considered
in the unweighted analyses. The intermediate confounding is controlled for using the MSM.
4.1. Effect of lagged variables
Analysis HR SE P-value 95% C.I
MSM2 0.14 0.22 0.00 [, ]
Table 4.3. MSM without lagged covariates of CD4 and RNA
The lagged variables of CD4 and RNA, i.e the measurements three months before the current
month, are used in the weighted analysis. It is interesting to check if the effect of treatment
changes when the lagged varibles are not used as covariates in the analysis. This is done in
Table 4.3. The hazard ratio is 0.14 compared to 0.15 as is the case when the lagged variables are
used. This is certainly not a big difference, so the lagged variables seem to have a tiny impact
on the effect estimate of HAART.
4.2. Stata/R
The making of the equivalent program in R was not too hard to do because of the analysis tools
in R. But the handling of two or more events in the same time interval, e.g ties, were different
in the two programs. The default method in Stata is the method of Breslow and the default
method in R is Efron. I chose Breslow’s method for the handling of ties. The event covariate
”aidsordeath” in the data set is either 0, 1 or ”.”. The dot means a censored event. The standard
procedure in R for missing data in a Cox analysis is to delete the lines with missing data, or a
”.”. To avoid the deleted lines in R, I put all the dots in the event covariate ”aidsordeath” to
zero and made an new indicator variable for censoring.
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Analysis HR SE P-value 95% C.I
(1) 0.75 0.20 0.13 [0.51, 1.10]
(2) 0.36 0.22 ≤ 0.001 [0.24, 0.55]
(3) 0.71 0.23 0.14 [0.45, 1.12]
Table 4.4. Unweighted Cox analyses in R
Analysis HR SE P-value 95% C.I
MSM 0.17 0.21 ≤ 0.001 [0.11, 0.26]
Table 4.5. Weighted Cox analysis in R
The results in Table 4.4 and Table 4.5 show small differences from the results in Stata, Table
4.1 and Table 4.2. The reason for the small differences is that Sterne has used splines to model
the change in the hazard with time. I have not done this in R. Except from the use of splines
I have made an equivalent program for the analyses in R and this program is used for further
analyses.
Table 4.6 gives a summary of the most important predictors for starting HAART.
22
4.2. STATA/R
HR P-value
Transmission group
Group 1 1 (reference)
Group 2 1.14 < 0.001
Group 3 0.57 < 0.001
Group 4 1.73 < 0.001
CD4 count
< 50 1 (reference)
50− 99 0.89 0.54
100− 199 0.63 0.01
200− 349 0.41 < 0.001
350− 499 0.36 < 0.001
500− 749 0.41 < 0.001
≥ 750 0.46 < 0.001
Lagged CD4 count
< 50 1 (reference)
50− 99 0.92 0.70
100− 199 0.73 0.13
200− 349 0.75 0.19
350− 499 0.64 0.05
500− 74 0.65 0.05
≥ 750 0.91 0.67
RNA copies
< 400 35.72 < 0.001
400− 1000 8.17 < 0.001
1′001− 10′000 2.48 < 0.001
10′001− 100′000 1.30 < 0.001
> 100′000 1 (reference)
Lagged RNA copies
< 400 3.28 < 0.001
400− 1000 1.27 0.01
1001− 10′000 0.88 0.08
10001− 100′000 1.01 0.85
> 100′000 1 (reference)
Table 4.6. Effect of covariates on starting HAART
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CHAPTER 5
Simulation and analyses
To show the use of the Marginal Structural Model I simulate a set of patients already diagnosed
with HIV followed for a period of three years.
γ=0.0833 
 
1 
       CD4 high 
      No treatment 
2 
       CD4 low 
      No treatment 
3 
       CD4 high 
      Treatment 
4 
       CD4 low 
      Treatment 
5 
       AIDS/DEATH 
α=0.0088 
ρ=0.0044 
  =0.0070   =0.0833 
  =0.0833 
  =0.0417 
Figure 5.1. Markov model
This is a very simple model with CD4 and treatment as the only covariates. The covariates
are used as information to describe the course of the disease, and the different stages follows a
multi-state Markov model with the state space and intensities given in Figure 5.1. The Greek
letters are the transition intensities between the different states of the model. The patients can
start in state 1, 2, 3 or 4. The model is based on the model for the development of AIDS and
HIV diagnosis of Aalen et al from 1997, [17], but very simplified. Towards the right of Figure
5.1 is the progression of the disease, ending with either AIDS or death being the same state.
Downwards is the start of a drug treatment that can be started in both stages of the disease. The
model is homogeneous over time to make it as simple as possible, meaning that the transitions
don’t depend on the times explicitly but on the length of the time interval. It is assumed that if
a patient starts treatment he stays on it. And it is not possible to move from low CD4 to high
CD4 without treatment.
The two stages of the HIV progression are
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• Stage I: CD4 ≥ 200 cells/µL, states 1 and 3
• Stage II: CD4 < 200 cells/µL, states 2 and 4
The occupancy is the percentage of time spent in a state against the (AVAILABLE TIME??).
The mean occupancy time, T, is then the mean time spent in the state. In the thesis of Odd
Aalen [17] there were used three stages with mean occupancy times 5.5 years, 4 years and 1
year. My idea is to sort of merge two of those stages together, resulting in two stages with mean
occupancy times 9.5 years and 1 year. The data set is split into monthly intervals and then the
transition intensity β is given as
β =
1
12× T
This gives the transition intensities β1 ≈ 0.0070 and β2 ≈ 0.0833.
The other parameters are fixed so that:
• the intensity of starting treatment is almost 12 times bigger with a low CD4 count than
with a high value
• the intensity for getting a low value of the CD4 count is two times bigger when off
treatment than on
• the intensity for getting AIDS or dying is two times bigger when off treatment than on
γ was set to a value that seemed reasonable.
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Figure 5.2. Follow up
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When individuals enter the study at different times, it causes left-truncation and when the study
is stopped at a certain time we get censored event times. Left-truncation is basically a delayed
entry, and censoring is missing data. We can summarize these calender time data to follow up
time. Figure 5.2 is a hypothetical clinical study with 10 patients. The filled circles indicate the
occurrence of the event, and the open circles indicate censoring. The follow uptime is used in
my simulation.
Q =
∣∣∣∣∣∣∣∣∣∣∣∣∣∣
−0.0158 0.0088 0.0070 0 0
0 −0.1667 0 0.0833 0.0833
0 0 −0.0044 0.0044 0
0 0 0.0833 −0.1250 0.0417
0 0 0 0 0
∣∣∣∣∣∣∣∣∣∣∣∣∣∣
Figure 5.3. Intensity matrix
The 5 × 5 intensity matrix Q for the course of the patients is given in Figure 5.3. The rows of
Q must sum up to zero, so the diagonal elements are the negative sum of each row.
From Markov theory [18] it is possible to find an explicit solution of the transition matrix P (t)
for a finite Markov chain given the intensity matrix Q. The theory is that P (t) = eQt where eQt
is called the matrix exponential.
The transition probabilities are defined as the probability of occupying state j at time t condi-
tional on occupying state i at time s.
pi,j(s, t) = Prob{X(t) = j|X(s) = i}, s < t
for i, j = 1, . . . , 5. But we have a time-homogeneous chain, and the probabilities are then denoted
as pi,j(t), being the probability of going from state i to state j in time t. These probabilities are
given as the (i, j) entries of P (t). For instance we have
P (1) =
∣∣∣∣∣∣∣∣∣∣∣∣∣∣
0.9843 0.0080 0.0070 0.0003 0.0003
0 0.8465 0.0031 0.0720 0.0783
0 0 0.9958 0.0041 ≈ 0
0 0 0.0782 0.8827 0.0392
0 0 0 0 1
∣∣∣∣∣∣∣∣∣∣∣∣∣∣
Figure 5.4. Intensity matrix
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These are the probabilities of moving between the states in time 1.
The survival matrix at time t is
S(t) = 1− P (t)
5.1. Theoretical analyses
I use R to find the transition matrices for 100 time points between 1 and 36 months and
compare the situation where the patients get a treatment offer and the situation where there
is no treatment offer. The first situation is given with the model in Figure 5.1 and the second
with β1 = β2 = 0.
Figure 5.8 gives the probabilities of going from state 1 to state 5 for the setting of a treatment
offer and for the setting of no treatment offer. The probability of going from state 1 to state 5
starts out the same for the two different settings until about month 5. From then the probability
is higher when there is no treatment offer than when there is one. This difference gets bigger
and bigger as time goes. Now I have a base for comparison of the results I get from further
analyses.
Figure 5.9 gives the corresponding survival function. It starts at 1 and then decreases slowly.
Figure 5.10 shows a decreasing hazard ratio, meaning that there is a treatment effect and that
it gets better and better with time.
5.2. Simulation of patients with random start
In the simulated data set there is 244 events and 756 censored events for the period of 3 years.
The set is simulated in continuous time.
(1) treatment as the only covariate
(2) treatment and baseline covariates
(3) treatment and time-updated covariates
5.2.1. Unweighted Cox Analysis. Table 5.1 shows the results for the Cox Analyses for
the random start set. There is a significant positive treatment effect for all three of the analyses.
For analysis no. 1 there is a decreased hazard for AIDS or death of 66% with the treatment
compared to no treatment. For analalysis no. 2 the hazard is reduced with 88% for the patients
on treatment. The hazard for the patients on treatment in the analysis no. 3 is 74% lower than
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Figure 5.5. p2,5(t): Probabilities of moving from state 2 to state 5, with and without
a treatment offer
Analysis no. HR SE z P-value 95% C.I
(1) 0.3406 0.1247 −8.636 ≤ 0.001 [0.2667, 0.4349]
(2) 0.1229 0.1859 −11.278 ≤ 0.001 [0.0854, 0.1770]
(3) 0.2618 0.1767 −7.582 ≤ 0.001 [0.1852, 0.3702]
Table 5.1. Unweighted Cox Analysis
for the no treatment group. The last hazard ratio is not correct because of the warning: ”Loglik
converged before variable 3; beta may be infinite”. This means that there is too little variation
in variable 3 which is the cd4 variable.
Analysis HR SE z P-value 95% C.I
Weighted 0.2571 0.1263 −10.7553 ≤ 0.001 [0.2008, 0.3293]
Table 5.2. Results from the weighted analysis, random start state
5.2.2. Weighted Cox Analysis. Table 5.2 shows that the odds for AIDS or death is
reduced with 74% for the patients on treatment compared to those off treatment. This is a very
good treatment estimate. The hazard ratio is a little higher than the one calculated by Sterne
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Figure 5.6. S2,5(t): Probabilities of not moving from state 2 to state 5, with and
without a treatment offer
et al [13] in their study. But they are barely comparable since the data set of Stern et al is a
whole lot bigger than my simulated sets.
5.3. Simulation of patients with start state 1
I simulate 1000 patients from the same Markov model in Figure 5.1 where all patients start in
state 1, i.e. all patients start with no treatment and high CD4 count. Only 64 patients end up
in state 5 which means they end up with either AIDS or death and 936 patients get censored.
Since all the patients start in the same state, there is no use in doing an analysis with the
baseline covariates since they are all the same for every patient. I do two different analyses for
each method:
(1) treatment as the only covariate
(2) treatment and time-updated covariates
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Figure 5.7. Hazard Ratio, start state 2
Analysis no. HR SE z P-value 95% C.I
(1) 0.9169 0.2026 −0.428 0.6680 [0.6164, 1.3640]
(2) 0.7431 0.2106 −1.410 0.1590 [0.4918, 1.1230]
Table 5.3. Unweighted Cox Analysis
5.3.1. Unweighted Cox Analysis. From the unweighted analyses in Table 5.3 the hazard
of AIDS or death is reduced with 8% when the baseline covariates are used and reduced with
26% when the time-dependent covariates are used. The last estimate cannot be trusted because
there is small variation in the CD4 count, and this gives a warning in R saying ”Loglik converged
before variable 2; beta may be infinite”. There is too little variation in the cd4 data to estimate
the treatment effect correctly. Maybe not so weird since everyone starts out in the same state.
5.3.2. Weighted Cox Analysis. It is not possible to make stable weights here since the
baseline covariates are all the same.From the Logistic analysis in Table 5.4 we can see that the
hazard for getting AIDS or dying is reduced with 69% for the patients on treatment. I don’t
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Figure 5.8. p1,5(t): Probabilities of moving from state 1 to state 5, with and without
a treatment offer
Analysis HR SE z P-value 95% C.I
Weighted 0.6198 0.2060 −2.32179 0.0202 [0.4139, 0.9282]
Table 5.4. Results from the weighted analysis, start state 1
know how accurate these results are if I analyze the weights used for the analyses. The weights
vary from 1 to 292. Some patients contribute to the set a huge amount of times compared to
others. And the density of the weights is very skewed as can be seen from the histogram. But
the patients all start out less sick and it then seems like the treatment is more effective.
5.4. Simulation of patients with start state 2
I simulated 1000 patients over three years where all the patients started in state 2. 550 patients
ended up death or with AIDS and 450 did not experience the event before the study time was
over, e.g. were censored.
5.4.1. Unweighted Cox Analysis.
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Figure 5.9. S1,5(t): Probabilities of not moving from state 1 to state 5, with and
without a treatment offer
Analysis no. HR SE z P-value 95% C.I
(1) 0.5189 0.1001 −6.555 ≤ 0.001 [0.4265, 0.6314]
(2) 0.6472 0.1084 −4.014 ≤ 0.001 [0.5234, 0.8004]
Table 5.5. Unweighted Cox Analysis
Analysis OR/HR SE z P-value 95% C.I
Weighted 0.8555 0.1028 −1.518 0.1290 [0.6993, 1.0465]∗
Table 5.6. Results from the weighted analysis, start state 2
5.4.2. Weighted Cox Analysis.
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Figure 5.10. Hazard Ratio, start state 1
5.5. Simulation of patients with start states 1 and 2
I simulate 1000 new patients from the Markov model where one half start out in state 1 and the
second half in state 2. They are followed up for a period of 3 years, and 295 patients end up in
state 5 which means they end up with either AIDS or death. 705 get censored.
The three different analyses for a unweighted Cox and pooled logistic are done again.
Analysis no. HR SE z P-value 95% C.I
(1) 6.8841 0.1427 13.52 ≤ 0.001 [5.2040, 9.1060]
(2) 3.5584 0.1561 8.131 ≤ 0.001 [2.6205, 4.8321]
(3) 3.6866 0.1564 8.341 ≤ 0.001 [2.7132, 5.0093]
Table 5.7. Unweighted Cox Analysis
5.5.1. Unweighted Cox Analysis. From the unweighted analyses in Table 5.7 the hazard
of AIDS or death is from 3 to 6 times higher for the patients on treatment. These estimates are
biased.
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Analysis OR/HR SE P-value 95% C.I
Cox 2.9930 0.1350 8.1219 ≤ 0.001 [2.2973, 3.8994]
Table 5.8. Results from the weighted analysis, start states 1 and 2
5.5.2. Weighted Cox Analysis.
5.6. Simulation of patients with start states 3 and/or 4
It makes no sense to do the analyses with patients who start in state 3 or 4, since they all start
with treatment.
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CHAPTER 6
Concluding Remarks
In the analyses for my thesis I show the use of the Marginal Structural Model. I estimate haz-
ard ratios by using weighted Cox proportional hazards models, controlling for time-dependent
confounding. The weights are calculated from the inverse of each patient’s probability of the
treatment history they actually had, given their covariate history. This gives me a weighted
set where the treatment probability is unrelated to the time-dependent confounders. The con-
founders are controlled by the weights and not as covariates in the Cox models. With this I
also avoid the problem that the confounders can be intermediate on the causal pathway from
HAART to the outcome of AIDS or death.
The analyses done in my thesis have several restrictions. For example there has been no placebo-
controlled randomized trial of HAART. The reason for this is of course because it wouldn’t be
ethically right to offer treatment to some patients and not to other patients when they all need
treatment. And in many studies the follow-up time has been of a year or less. With this the
effectiveness of HAART over several years is still unknown. The use of the MSM gives an
estimate of the effect over several years, but there is maybe no way of knowing how good the
estimation is because of the ethical restrictions. Another thing could be the use of CD4 count
and viral load as markers for progression to AIDS or death. In my thesis I have assumed that
these measures are good enough as markers...(kanskje det fins en artikkel som diskuterer dette...)
Standard methods for estimating the causal effect of treatment on AIDS or death will produce
biased estimates:
(1) The crude estimate without control for confounding is biased because the subjects on
HAART usually have a low CD4 count, and subjects with low count values have higher
AIDS and death rates
(2) The estimate when controlling for baseline values such as the CD4 count at baseline
will give biased results bacause the fact that the subjects starting on HAART had low
CD4 counts is ignored
(3) Controlling for the time-dependent confounders such as the CD4 count will produce
biased estimates because HAART will partly make the CD4 counts higher
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